We do follow it, though -- because a clearly multi-billion dollar Lanham Act trial will take place later this year, in New Jersey's federal courts -- over which of these behemoths properly owns the right to use the name "Merck". [And yes, it has been going on since the Treaty of Versailles in 1917 -- you can find over 100 posts on that topic here by searching in the upper left.]
In any event, here is the estimable FiercePharma, with the latest -- and a bit:
. . .Garijo will bring “increased rigor” to implementing the company’s strategy, Sanofi explained in an early-morning press release. Garijo’s priority will be to strengthen the productivity, governance and innovation capacity for R&D, the Paris-based pharma added. . . .
Garijo joined French pharmaceutical company Rhône-Poulenc Rorer in 1996, moved to Aventis after the companies merged and ended up at Sanofi as the result of another takeover. Sanofi said Garijo led the integration of Genzyme before leaving to join Merck KGaA in 2011. Garijo was born in 1960, and Sanofi will need to change its articles of association to raise its CEO age limit upon appointment before she takes the post.
Freeing up Garijo to take the top Sanofi post is the separate leadership transition taking place at Merck KGaA. In September, the German healthcare and electronics conglomerate announced that Garijo would conclude her five-year tenure as chief executive at the end of April, as planned. Kai Beckmann, who is currently the company's CEO of electronics, will take over as Merck KGaA's new group CEO May 1. . . .
That's probably the end of power alley stuff for today. Smile -- as now, chocolates await, with fresh deeply-red cherries and piping hot coffee!
नमस्ते
No comments:
Post a Comment